Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Ascentage Pharma Group Corp Limited is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct art units, which indicates a range of pharmaceutical or biological subject matter under review. The company's prosecution involves 6 distinct examiners, meaning that every pending action is assigned to a different official. The busiest examiner for the portfolio is WITHERSPOON, SIKARL A, who is currently overseeing 1 pending office action.
This distribution shows that no 1 examiner holds a majority of the company's active cases. The ratio of 6 pending actions to 5 art units suggests that most technical categories are receiving individual attention from the patent office. For the applicant, this necessitates a strategy that accounts for the specific nuances of 5 different art units and the individual tendencies of 6 different examiners. The lack of concentration in examiner assignments prevents any 1 examiner from having a disproportionate impact on the overall portfolio's progress. This diversity requires a versatile approach to responding to office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WITHERSPOON, SIKARL A | 1 | 86.2% | -20.1% |
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727848 | METHODS FOR TREATING AML-MRC AND MDS | WITHERSPOON, SIKARL A | — |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269301 | METHODS OF TREATING MULTIPLE SCLEROSIS | SHIM, DAVID M. | 51d overdue |
| 17921257 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | HEITMEIER, KENDALL NICOLE | 2d overdue |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | OH, TAYLOR V | — |
| 18250861 | A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof | SHOWALTER, ALEXANDER KEITH | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1626 | 1 |
| 1629 | 1 |
| 1621 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727848 | METHODS FOR TREATING AML-MRC AND MDS | WITHERSPOON, SIKARL A | — | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18294510 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | OH, TAYLOR V | 1625 | §102§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18269301 | METHODS OF TREATING MULTIPLE SCLEROSIS | SHIM, DAVID M. | 1626 | §103 | Final Rejection | 51d overdue | Pending | Jun 23, 2023 |
| 18250861 | A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof | SHOWALTER, ALEXANDER KEITH | 1629 | §103DP | Non-Final OA | — | Pending | Apr 27, 2023 |
| 17921257 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | HEITMEIER, KENDALL NICOLE | 1621 | §102 | Final Rejection | 2d overdue | Pending | Oct 25, 2022 |
| 17918557 | NOVEL MEDICAL USE OF MDM2 INHIBITORS | NOLAN, JASON MICHAEL | 1600 | §103DP | Final Rejection | — | Pending | Oct 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial